Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
SGLT-2 inhibitors and most GLP-1 receptor agonists demonstrated cardiovascular superiority and reduction of cardiovascular and overall mortality. These results stand as a turning point in the management of diabetes, shifting the focus from controlling glucose levels to mastering the extra-glycemic effects of these new drugs. This narrative review will discuss recent CVOT with focus on SGLT-2 inhibitors and GLP-1 receptor agonists to distinguish relevant patients' characteristics as potential predictors for therapeutic efficacy.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Francesco Giorgino, Irene Caruso, Julia Moellmann, Michael Lehrke Source Type: research
More News: Biomedical Science | Cardiology | Cardiovascular | Congestive Heart Failure | Diabetes | Endocrinology | Heart | Heart Disease | Heart Failure